Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring

• Published in: Hematology, Transfusion and Cell Therapy Vol. 43; no. 2; pp. 191 - 200
• Main Authors: Seguro, Fernanda Salles, Silva, Carolina Maria Pinto Domingues Carvalho, Moura, Carla Maria Boquimpani de, Conchon, Monika, Fogliatto, Laura, Funke, Vaneuza Araujo Moreira, Abdo, André, Macedo, Ariane Vieira Scarlatelli, Santos, Marilia Harumi Higushi dos, Saraiva, José Francisco Kerr
• Format: Journal Article
• Language: English
• Published: Elsevier España, S.L.U 01.04.2021; Sociedade Brasileira de Hematologia e Hemoterapia; Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH); Elsevier
• Subjects: Cardiovascular diseases; Leukemia, myeloid; MEDICINE, GENERAL & INTERNAL; Protein kinase inhibitors; Review; Risk factors; Risk management; Leukemia, myeloid; Cardiovascular diseases; Protein kinase inhibitors; Risk management; Risk factors
• ISSN: 2531-1379; 2531-1387; 2531-1387
• DOI: 10.1016/j.htct.2020.04.009

This manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors (TKIs) from the point of view of clinical practice and from the perspective of hematology consultation. In the first medical appointment, the CV risk factors should be identified to perform the baseline risk stratification, based on the Brazilian Guideline of Dyslipidemia and Atherosclerosis Prevention Update (risk levels: very high, high, intermediate and low). Once stratified, the treatment of the CV risk factors should be administered. If the patient presents risk factors, such as hypertension, diabetes, renal disease, smoking and hypercholesterolemia, the evaluation and initial treatment may be done by the hematologist, being an option the request for evaluation by a specialist. If the patient has a history of previous CV disease, we recommend referral to a specialist. As the CV risk score is dynamic and the control of risk factors can reduce the patient risk, this expert consensus recommends that the re-evaluation of the CV risk after the baseline should be performed at 3 months, 6 months and 12 months. After this period, it should be done annually and, for specific patients, at the clinician’s discretion. The evaluation of the baseline CV risk and the safe administration of a TKI allow the patient to benefit from the maximum treatment, avoiding unwanted effects.